Jessica Friedlin, PA
Physician Assistant · Anderson, INNPI 1396324091
Payments from drug & device makers
Across 395 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$655
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$608
- Johnson & Johnson$495
- Ardelyx, Inc.$407
- Pfizer$314
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,27298%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 155 | $1,716 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $655 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $608 |
| Johnson & Johnson | 22 | $495 |
| Ardelyx, Inc. | 19 | $407 |
| Pfizer | 25 | $314 |
| Lilly USA, LLC | 11 | $274 |
| Madrigal Pharmaceuticals | 10 | $260 |
| Vivus LLC | 9 | $176 |
| Regeneron Healthcare Solutions, Inc. | 7 | $166 |
| Phathom Pharmaceuticals, Inc. | 7 | $162 |
| Gilead | 7 | $143 |
| Aimmune Therapeutics, Inc. | 5 | $130 |
| Sanofi | 4 | $128 |
| QOL Medical, LLC | 6 | $123 |
| Merck | 6 | $119 |
| Ipsen Biopharmaceuticals, Inc | 4 | $73 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Bristol Myers Squibb | 3 | $49 |
| Ferring Pharmaceuticals Inc. | 3 | $43 |
| Braintree Laboratories, Inc. | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $31 |
| Redhill Biopharma Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Celltrion USA Inc. | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Echosens North America, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,369 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 64 | $213,463 |
| LinzessLinaclotide | 132 | $146,017 |
| XifaxanRifaximin | 29 | $87,598 |
| RezdiffraResmetirom | 16 | $62,965 |
| MotegrityPrucalopride Succinate | 45 | $47,377 |
| Mesalamine | 37 | $23,150 |
| Lubiprostone | 147 | $17,240 |
| Dexlansoprazole DrDexlansoprazole | 49 | $17,201 |
| Pantoprazole Sodium | 238 | $10,340 |
| Mesalamine ErMesalamine | 20 | $8,493 |
| MovantikNaloxegol Oxalate | 15 | $6,811 |
| ErythromycinErythromycin Base | 12 | $5,403 |
| Omeprazole | 273 | $4,313 |
| Ursodiol | 13 | $3,921 |
| Ondansetron OdtOndansetron | 131 | $3,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,716 | $359,481196 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $608 | $87,59829 claims |
| Madrigal PharmaceuticalsRezdiffra | $260 | $62,96516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $655 | $47,37745 claims |
| Redhill Biopharma Inc.Movantik | $22 | $6,81115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Anderson
- Kristen GumpfCarmel$142K
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Lauren HoweMunster$28K
- A FergusonFort Wayne$22K
- Jacquelyn BeemerFort Wayne$21K
- Lindsay YoderIndianapolis$21K
- Eryn GormanClinton$18K
- Audrey HewittBloomington$17K
- Mackenzie LawsonIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.